AGN

5 Drug Stocks to Buy While the Pharma Sector Is on Sale

By Luke Lango, InvestorPlace Senior Investment Analyst
Drug stocks have been beaten up ever since the 2015 collapse of Valeant, but many of them are now too cheap to ignore.

Allergan Stock Is Worth a Look for Long-Term Investors

By Luke Lango, InvestorPlace Senior Investment Analyst
The short-term outlook on AGN stock is messy due to drug pricing issues. But the long-term outlook remains promising - thanks to the company's wide moat and stable growth prospects.

5 Pharmaceutical and Biotech Stocks to Consider for July

By Chris Lau, InvestorPlace Contributor
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.

Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play

By Chris Lau, InvestorPlace Contributor
Teva Pharmaceuticals is quietly moving higher on the stock market for good reason: worries over pricing and the impact of competition in generics is getting clearer. Teva stock is a great long-term bet.

What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month

By Chris Lau, InvestorPlace Contributor
Axovant Sciences soared last week after AXON stock presented AXO-Lenti-PD, a gene therapy product that treats Parkinson's Disease.

Allergan plc Stock Becomes a Buy as It Bottoms Out

By Chris Lau, InvestorPlace Contributor
Allergan (AGN) raised its quarterly and yearly outlook but the stock slumped in trading after the earnings announcement. A big write-down is hammering the stock price.

Allergan plc Earnings: 10 Things to Know

By William White, InvestorPlace Writer
Allergan (AGN) released its earnings report for the first quarter of the year of Monday and InvestorPlace has some highlights from it.

Allergan plc Stock Looks Cheap for Good Reasons

By Vince Martin, InvestorPlace Contributor
Allergan stock has slid steadily since last summer. With upside likely limited in the near-term, AGN isn't a falling knife worth catching.

10 Stocks Hedge Funds Are Buying

By Todd Shriber, InvestorPlace Contributor
Some hedge fund managers perform well. If you want to learn from their example, here are some of hedge funds' favorite stocks at the moment.

Revance Therapeutics Inc Is Set to Shake Up the Botox Market

By Chris Lau, InvestorPlace Contributor
RVNC has an edge with its formulation of Botox: it lasts longer. Given the little innovation in the botulinim toxin market, Revance has a real chance to succeed.

Mylan N.V. Stock Is Headed Back Down to $40

By Joseph Hargett, InvestorPlace Contributor
Despite a wealth of bullish news since the beginning of March, MYL stock remains capped by this key trendline ... and it will send Mylan shares lower as a result.

Strong Sell for Allergan (AGN) This Week

By Portfolio Grader
At $163.19, Allergan (AGN) a Strong Sell based on the latest comparative pricing of its shares and analysis.

Strong Sell for Allergan (AGN) This Week

By Portfolio Grader
At $150.69, Allergan (AGN) a Strong Sell based on the most current stock market ratings, and comparative pricing of its shares.

Allergan (AGN) a Strong Sell at $148.73

By Portfolio Grader
The Strong Sell for Allergan (AGN) this week is based on the most recent news, and relative pricing of its shares.

At $159.86, Allergan (AGN) a Strong Sell

By Portfolio Grader
The Strong Sell for Allergan (AGN) this week is based on the latest comparative pricing of its shares and news.

7 Top Takeover Targets for 2018

By Harriet Lefton, Writer, TipRanks
Morgan Stanley listed 15 prime takeover candidates for the next 12 months and TipRanks shows us which among those are your best investing bets.

10 Secret Stocks Top Investors Are Betting On

By Harriet Lefton, Writer, TipRanks
Here are the 10 stock picks top investors are betting on right now. We take a look at how investors are trading these stocks -- and whether the Street agrees.

Despite Tax-Cut, Pfizer Inc. Remains a Slow-Growth Company

By Dana Blankenhorn, InvestorPlace Contributor
While PFE stock jumped on gains from the Trump tax cut, Pfizer is still a slow-growth company. Income investors should wait for the price to come down before investing in PFE stock.

Stocks Set for Record Run as Risks Multiply

By Anthony Mirhaydari, InvestorPlace Market Strategist
Stocks are set to keep running higher, but that doesn't mean all the risks have disappeared. Here's what investors need to know.
Load More